Humacyte (HUMA) Stock Statistics & Valuation Metrics

Humacyte has a market cap or net worth of $216.16M. The enterprise value is $306.40M.

Humacyte has 192,996,500 shares outstanding. The number of shares has decreased by -2.65% in one year.

Humacyte’s return on equity (ROE) is 2.82 and return on invested capital (ROIC) is -94.67%.

The current PE Ratio of Humacyte is ―. Humacyte’s PEG ratio is -0.23.

In the last 12 months, Humacyte had revenue of 0.00 and earned -148.70M in profits. Earnings per share was -1.26.

In the last 12 months, operating cash flow was -105.50M and capital expenditures -908.00K, giving a free cash flow of -106.40M billion.

Humacyte pays an annual dividend of ―, resulting in a dividend yield of ―

Humacyte upcoming earnings date is Mar 26, 2026, Before Open (Confirmed).

Humacyte as a current ratio of 2.40, with Debt / Equity ratio of -627.76%

In the past 12 months, Humacyte has paid 0.00 in taxes.

Humacyte EV to EBITDA ratio is -4.31, with an EV/FCF ratio of -5.72.

Humacyte has $19.49M in cash and marketable securities with $29.82M in debt, giving a net cash position of -$10.34M billion.

Gross margin is 4.32%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Humacyte is $5.88, which is 11.43% higher than the current price. The consensus rating is Strong Buy